These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9587856)

  • 21. Cardiac valve replacement: a bioengineering approach.
    Korossis SA; Fisher J; Ingham E
    Biomed Mater Eng; 2000; 10(2):83-124. PubMed ID: 11086842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective randomized comparison of CarboMedics and St. Jude Medical bileaflet mechanical heart valve prostheses: ten-year follow-up.
    Bryan AJ; Rogers CA; Bayliss K; Wild J; Angelini GD
    J Thorac Cardiovasc Surg; 2007 Mar; 133(3):614-22. PubMed ID: 17320553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of pregnancy after bioprosthetic valve replacement in young women: a prospective five-year study.
    Avila WS; Rossi EG; Grinberg M; Ramires JA
    J Heart Valve Dis; 2002 Nov; 11(6):864-9. PubMed ID: 12479290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Progress in prosthetic heart valves].
    Komatsu S; Inoue N
    Nihon Rinsho; 1986 Jul; 44(7):1698-707. PubMed ID: 3531626
    [No Abstract]   [Full Text] [Related]  

  • 26. Update of the European standards for inactive surgical implants in the area of heart valve prostheses.
    Eichinger W; Däbritz S; Lange R
    Eur J Cardiothorac Surg; 2007 Nov; 32(5):690-5. PubMed ID: 17870610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of design on bioprosthetic valve durability.
    Vesely I
    J Long Term Eff Med Implants; 2001; 11(3-4):137-49. PubMed ID: 11921660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statistical methodology used in the TAXUS ATLAS Trial.
    Turco MA; Ormiston JA
    J Am Coll Cardiol; 2009 Jan; 53(3):296-7. PubMed ID: 19147050
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients.
    Cen YY; Glower DD; Landolfo K; Lowe JE; Davis RD; Wolfe WG; Pieper C; Peterson B
    J Thorac Cardiovasc Surg; 2001 Sep; 122(3):569-77. PubMed ID: 11547311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Food and Drug Administration-approved endovascular repair devices for abdominal aortic aneurysms: a review.
    Tan JW; Yeo KK; Laird JR
    J Vasc Interv Radiol; 2008 Jun; 19(6 Suppl):S9-S17. PubMed ID: 18502391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revised precautionary measures to reduce the possible transmission of Creutzfeldt-Jakob disease (CJD) by blood and blood products; guidance document; availability--FDA. Notice.
    Fed Regist; 1997 Sep; 62(184):49694-5. PubMed ID: 10173801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of pressure- and volume-loss of technical and biological heart valve prostheses.
    Köhler J
    Z Kardiol; 1986; 75 Suppl 2():272-6. PubMed ID: 3727699
    [No Abstract]   [Full Text] [Related]  

  • 33. Seventeen-year clinical results of 1,037 Mitroflow pericardial heart valve prostheses in the aortic position.
    Yankah CA; Schubel J; Buz S; Siniawski H; Hetzer R
    J Heart Valve Dis; 2005 Mar; 14(2):172-9; discussion 179-80. PubMed ID: 15792176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In response to: Grunkemeier GL, Starr A. Alternatives to randomization in surgical studies.
    Blackstone EH
    J Heart Valve Dis; 1993 Jan; 2(1):119-22. PubMed ID: 8269104
    [No Abstract]   [Full Text] [Related]  

  • 35. Use and recognition of consensus standards in US premarket submissions.
    Donawa ME
    Med Device Technol; 1999 Mar; 10(2):13-7. PubMed ID: 10387610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quattro valve trial at mid-term: December 1996 to November 2004.
    Frater RW; Sussman M; Middlemost S; Walther T; Mohr F; Al Halees Z; Shahid M
    J Heart Valve Dis; 2006 Mar; 15(2):230-7; discussion 237. PubMed ID: 16607906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with the 3F stentless aortic bioprosthesis: one-year follow up.
    Linneweber J; Kossagk C; Rogge ML; Dushe S; Dohmen P; Konertz W
    J Heart Valve Dis; 2006 Jul; 15(4):545-8. PubMed ID: 16901052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. US quality system requirements for software validation.
    Donawa ME
    Med Device Technol; 1998 Mar; 9(2):17-20. PubMed ID: 10186973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. International conference on harmonisation; guidance on statistical principles for clinical trials; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(179):49583-98. PubMed ID: 10185190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [In vitro assessment of bioprosthetic valve performance with the concentric creep of the stent post].
    Akiyama K; Sawatani O; Imamura E; Koyanagi H
    Nihon Kyobu Geka Gakkai Zasshi; 1988 Sep; 36(9):1978-84. PubMed ID: 3204285
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.